MCID: VRL011
MIFTS: 55

Viral Infectious Disease malady

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Viral Infectious Disease

Summaries for Viral Infectious Disease

MedlinePlus : 41 viruses are capsules with genetic material inside. they are very tiny, much smaller than bacteria. viruses cause familiar infectious diseases such as the common cold, flu and warts. they also cause severe illnesses such as hiv/aids, smallpox and hemorrhagic fevers. viruses are like hijackers. they invade living, normal cells and use those cells to multiply and produce other viruses like themselves. this eventually kills the cells, which can make you sick. viral infections are hard to treat because viruses live inside your body's cells. they are "protected" from medicines, which usually move through your bloodstream. antibiotics do not work for viral infections. there are a few antiviral medicines available. vaccines can help prevent you from getting many viral diseases. nih: national institute of allergy and infectious diseases

MalaCards based summary : Viral Infectious Disease, also known as arbovirus infections, is related to hepatitis c virus and venezuelan hemorrhagic fever, and has symptoms including fever, pruritus and pathological conditions, signs and symptoms. An important gene associated with Viral Infectious Disease is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A disease by infectious agent that results_in infection, has material basis in Viruses.

Related Diseases for Viral Infectious Disease

Diseases related to Viral Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 266)
id Related Disease Score Top Affiliating Genes
1 hepatitis c virus 32.8 CCR5 DDX58 IFIH1 IFNA1 IRF3 MX1
2 venezuelan hemorrhagic fever 31.7 IFNG IL2 TNF
3 powassan encephalitis 31.7 CD40LG MX1 TNF
4 nasopharyngitis 31.7 IFNG IL2 TLR9 TNF
5 newcastle disease 31.7 CD40LG IL2 TLR9 TNF
6 argentine hemorrhagic fever 31.7 CCR5 CXCL10 IL10 TLR3
7 plantar wart 31.7 IFNG IL10 IL2 TNF
8 severe acute respiratory syndrome 31.7 DDX58 IFNA1 IFNB1 IRF3 IRF7
9 zika virus infection 12.3
10 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection and neoplasia 12.2
11 immunodeficiency 31b, mycobacterial and viral infections, autosomal recessive 12.2
12 chronic active epstein-barr virus infection 12.2
13 congenital herpes simplex virus infection 12.0
14 hendra virus infection 12.0
15 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.9
16 x-linked magnesium deficiency with epstein-barr virus infection and neoplasia 11.9
17 congenital epstein-barr virus infection 11.9
18 nipah virus disease 11.9
19 simian b virus infection 11.8
20 autoimmune lymphoproliferative syndrome, type iib 11.6
21 lymphocytic choriomeningitis 11.0
22 tick-borne encephalitis 10.9
23 panencephalitis, subacute sclerosing 10.7
24 dengue disease 10.7
25 hepatitis b 10.7
26 chikungunya 10.7
27 la crosse encephalitis 10.7
28 bolivian hemorrhagic fever 10.7
29 brazilian hemorrhagic fever 10.7
30 chapare hemorrhagic fever 10.7
31 whitewater arroyo hemorrhagic fever 10.7
32 lujo hemorrhagic fever 10.7
33 alkhurma hemorrhagic fever 10.7
34 exanthema subitum 10.7
35 o'nyong'nyong fever 10.7
36 barmah forest virus disease 10.7
37 ross river fever 10.7
38 oropouche fever 10.7
39 zika fever 10.7
40 louping ill 10.7
41 mumps 10.7
42 common cold 10.7
43 eastern equine encephalitis 10.7
44 murray valley encephalitis 10.7
45 western equine encephalitis 10.7
46 japanese encephalitis 10.7
47 st. louis encephalitis 10.7
48 hand, foot and mouth disease 10.7
49 epidemic pleurodynia 10.7
50 herpangina 10.7

Graphical network of the top 20 diseases related to Viral Infectious Disease:



Diseases related to Viral Infectious Disease

Symptoms & Phenotypes for Viral Infectious Disease

UMLS symptoms related to Viral Infectious Disease:


fever, pruritus, pathological conditions, signs and symptoms

MGI Mouse Phenotypes related to Viral Infectious Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ITIH4 TLR7 TLR9 TNF CCR5 CD40LG
2 hematopoietic system MP:0005397 10.24 CCR5 CD40LG CXCL10 DDX58 IFIH1 IFNB1
3 homeostasis/metabolism MP:0005376 10.22 IFNG IL10 IL2 IRF3 IRF7 MAVS
4 immune system MP:0005387 10.16 IL2 IRF3 IRF7 MAVS TLR3 TLR7
5 digestive/alimentary MP:0005381 10.01 IFNG IL10 IL2 MAVS TLR9 TNF
6 mortality/aging MP:0010768 9.8 CCR5 CD40LG CXCL10 DDX58 IFIH1 IFNG
7 liver/biliary system MP:0005370 9.76 CCR5 DDX58 IFIH1 IFNG IL10 IL2
8 neoplasm MP:0002006 9.28 CCR5 DDX58 IFNB1 IFNG IL10 IL2

Drugs & Therapeutics for Viral Infectious Disease

Drugs for Viral Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 865)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
4
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
5
Zinc Approved Phase 4,Phase 3,Phase 1,Phase 2 7440-66-6 32051 23994
6
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
8
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
9
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
10
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159989-64-7 64143
11
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
12
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
13
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
14
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
15
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
16
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
17
chloroquine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
18
Zidovudine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 30516-87-1 35370
19
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
20
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
21
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
22
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 134678-17-4 60825
23
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
24
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
25
Candesartan Approved Phase 4 139481-59-7 2541
26
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
27
Neomycin Approved, Vet_approved Phase 4,Phase 1,Phase 2 1404-04-2 8378
28
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
29
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
30
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
31
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
32
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
33
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
34
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 136470-78-5 65140 441300
35
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
37
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
38
Isoniazid Approved Phase 4,Phase 3,Phase 2 54-85-3 3767
39
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83905-01-5 55185 53477736 447043
40
Oseltamivir Approved Phase 4,Phase 3,Phase 2,Phase 1 204255-11-8, 196618-13-0 65028
41
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
42
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
43
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 376348-65-1 3002977
44
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 159519-65-0 16130199
45
Amantadine Approved Phase 4,Phase 3,Phase 1,Phase 2 768-94-5 2130
46
Abatacept Approved Phase 4 332348-12-6 10237
47
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
48
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1 635728-49-3, 206361-99-1 213039
49
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
50
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269

Interventional clinical trials:

(show top 50) (show all 5230)
id Name Status NCT ID Phase
1 Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Unknown status NCT01954810 Phase 4
2 Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine Unknown status NCT01398540 Phase 4
3 Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. Unknown status NCT01063608 Phase 4
4 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4
5 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4
6 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4
7 The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A Unknown status NCT01127282 Phase 4
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4
9 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4
10 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Unknown status NCT01488526 Phase 4
11 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4
12 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4
13 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4
14 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4
15 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
16 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4
17 Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines Unknown status NCT01119157 Phase 4
18 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4
19 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
20 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
21 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
22 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4
23 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4
24 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4
25 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
26 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4
27 Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study Unknown status NCT00936013 Phase 4
28 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
29 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
30 7-valent Pneumococcal Conjugated Vaccination Unknown status NCT00885625 Phase 4
31 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4
32 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
33 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4
34 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
35 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4
36 The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling Unknown status NCT01843478 Phase 4
37 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
38 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
39 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4
40 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4
41 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
42 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4
43 Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Unknown status NCT00940940 Phase 4
44 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4
45 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
46 A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients. Unknown status NCT01736761 Phase 4
47 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4
48 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4
49 Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients Unknown status NCT01512056 Phase 4
50 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4

Search NIH Clinical Center for Viral Infectious Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: arbovirus infections

Genetic Tests for Viral Infectious Disease

Anatomical Context for Viral Infectious Disease

Publications for Viral Infectious Disease

Articles related to Viral Infectious Disease:

id Title Authors Year
1
Evolutionary analysis of the dynamics of viral infectious disease. ( 19564871 )
2009
2
Viral infectious disease and natural products with antiviral activity. ( 22504360 )
2007
3
IL12 in acute viral infectious disease. ( 8839166 )
1995

Variations for Viral Infectious Disease

Expression for Viral Infectious Disease

Search GEO for disease gene expression data for Viral Infectious Disease.

Pathways for Viral Infectious Disease

Pathways related to Viral Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CCR5 CD40LG CXCL10 DDX58 IFIH1 IFNA1
2
Show member pathways
13.73 CCR5 CD40LG CXCL10 IFNA1 IFNA2 IFNB1
3
Show member pathways
13.48 CCR5 CD40LG CXCL10 IL10 IL2 TLR3
4
Show member pathways
13.43 CCR5 CD40LG CXCL10 DDX58 IFNA1 IFNA2
5
Show member pathways
13.35 IFNA1 IFNA2 IFNB1 IL2 IRF3 IRF7
6
Show member pathways
13.07 IFNA1 IFNA2 IFNB1 IRF3 IRF7 MAVS
7
Show member pathways
12.93 CD40LG IFNA1 IFNA2 IFNG IL10 IL2
8
Show member pathways
12.85 CXCL10 DDX58 IFIH1 IFNA1 IFNA2 IFNB1
9
Show member pathways
12.84 CXCL10 DDX58 IFIH1 IFNA1 IFNA2 IFNB1
10
Show member pathways
12.79 CXCL10 DDX58 IFIH1 IFNA1 IFNA2 IFNB1
11
Show member pathways
12.78 CD40LG IL2 TLR3 TLR7 TLR9 TNF
12
Show member pathways
12.7 CD40LG IRF3 IRF7 TLR3 TLR7 TLR9
13
Show member pathways
12.67 CD40LG IFNG IL10 IL2 TNF
14
Show member pathways
12.64 DDX58 IFNA1 IFNA2 IFNB1 IFNG IRF3
15
Show member pathways
12.6 IFNA1 IFNA2 IFNB1 IFNG IL2 TNF
16
Show member pathways
12.52 DDX58 IFIH1 IRF3 IRF7 MAVS TLR3
17
Show member pathways
12.52 CCR5 CD40LG IFNG IL10 IL2 TNF
18
Show member pathways